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Background:  High proportions of stable hypertrophic cardiomyopathy (HCM) patients have elevated serum cardiac troponin I (cTnI), 
a maker of myocardial damage. Global longitudinal strain (GLS) identifies early systolic abnormalities in HCM but its use is limited to 
experienced centers. Data regarding elevated cTnI as a predictor for echocardiographic abnormalities, especially GLS in HCM patients, is 
lacking.
methods: We retrospectively interrogated clinical and echocardiographic data of stable HCM patients at our center from 01/2011 to 
03/2014. cTnI >0.04 was considered positive (cTNI+) and GLS > -18 as normal.
results:  Of 170 HCM patients, 36% were cTnI+ and 64% cTnI negative. Among cTnI+ patients, median cTnI was 0.11 ± 0.06 ng/dl. 
Clinical variables associated with cTnI+ included elevated brain natriuretic peptide (213 vs. 89, p<0.01) and implantable defibrillator (36% 
vs. 22%, p=0.05), while echocardiographic variables included mid (13% vs 3.7%, p=0.03) and apical (16.4% vs 9.2%, p=0.11) HCM, 
increased maximal LV thickness (2.4 vs. 2.1, p<0.01), lower septal E’ (4.9 vs 5.6, p=0.03) and reduced GLS (-13.7 vs. -16.5, p<0.01). GLS 
was reduced in 65% HCM patients, 41% were cTnI+. On linear regression, abnormal cTnI level was independently associated with reduced 
GLS (Table), with a positive predictive value of 85%.
conclusion:  Troponin level may be a simple biomarker to assess early systolic abnormalities in HCM, since it is an independent predictor 
of reduced GLS with a positive predictive value of 85%.
Table: Linear regression model examining the differences in global longitudinal strain (n=154)
Effect Estimate SE t P
Intercept (average GLS) -17.546 1.737 -10.1 <.0001
Troponin Positive 1.755 0.700 2.51 0.0135
Max LV Wall Thickness 1.740 0.595 2.92 0.0041
E’’ Septal -0.448 0.152 -2.95 0.0038
Variables considered for multivariate analysis: Age, gender, troponin, LV thickness, E’ Septal, Type of HCM (Obstructive/Non obstructive)
HCM = hypertrophic cardiomyopathy; LV = left ventricular; SE = standard error
